Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 27, Number 12—December 2021
Research Letter

Postmortem Stability of SARS-CoV-2 in Mouse Lung Tissue

Sophie A. Valkenburg, Samuel M.S. Cheng, Asmaa Hachim, Malik Peiris, and John NichollsComments to Author 
Author affiliation: The University of Hong Kong, Hong Kong, China

Suggested citation for this article

Abstract

The infectivity of severe acute respiratory syndrome coronavirus 2 in deceased persons and organisms remains unclear. We studied transgenic K18 hACE2 mice to determine the kinetics of virus infectivity after host death. Five days after death, virus infectivity in the lung declined by >96% and RNA copies declined by 48.2%.

The safe handling and disposal of bodies of persons who have died of coronavirus disease (COVID-19) is vital for infection control. Although cremation or burial practices are mainly dictated by religious and societal customs, deaths associated with contagious illness warrant appropriate precautions. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, is rapidly inactivated (>2 log10) within hours on nonporous surfaces (1). In addition, several studies have detected viral RNA by reverse transcription PCR (RT-PCR) of nasopharyngeal and pharyngeal mucosal swab specimens, skin swab specimens, and tissue samples collected during autopsies at different times after death (25). Furthermore, infectious virus was isolated in 2 of 4 cases at 4–17 days postmortem; however, this study did not quantify virus titers to determine the loss of virus infectivity (6). A separate study found that infectious virus was undetectable after exhumation at 3–4 months postmortem (7). Overall, RNA detection by RT-PCR might not directly correlate with virus infectivity or duration of symptomatic disease.

Transgenic K18-hACE2 mice provide a surrogate model to study the kinetics of SARS-CoV-2 viral replication during infection (8) and after host death. In humans and K18-hACE2 mice, little evidence exists for extrapulmonary dissemination of SARS-CoV-2, except for neurotropism in younger mice, a finding that has not been demonstrated reliably in humans. We investigated the temporal decay of infectious SARS-CoV-2 in postmortem tissues of infected K18-hACE2 mice. All experimental procedures were conducted in accordance with the standards and approved by the Committee on the Use of Live Animals in Teaching and Research (approval no. 5511-20) at The University of Hong Kong (Hong Kong, China).

Figure

Postmortem stability of severe acute respiratory syndrome coronavirus 2 in mouse lung tissue. A) Infectious virus measured by TCID50 of VeroE6 cells. B) Viral RNA measured by copies of N gene detected by RT-PCR. C) Percentage change compared with day 0. D) Correlation between infectious virus and viral RNA. R2 = 0.51; F = 0.005 by analysis of variance. NS, not significant; RT-PCR, reverse transcription PCR; TCID50, 50% tissue culture infectious dose.

Figure. Postmortem stability of severe acute respiratory syndrome coronavirus 2 in mouse lung tissue. A) Infectious virus measured by TCID50of VeroE6 cells. B) Viral RNA measured by copies of...

We infected twelve 14–20-week-old mice with 1 × 104 50% tissue culture infectious dose (TCID50)/25μL SARS-CoV-2 by the intranasal route. Five days later, after the mice had lost 18.8% (SD 7.77%) of their body weight, we euthanized them by ketamine/xylazil anesthesia. We wrapped each carcass in a sealable plastic bag, similar to the storage of human corpses, and stored them intact at 4°C, which is standard mortuary temperature. On days 0, 1, 5, and 14 after death, we dissected 3 carcasses and tested the lung tissue for coronavirus nucleoprotein (N) by histologic and immunohistochemistry assays (9) (Appendix Figure, panels A–H). We quantified infectious virus by culture (Figure, panel A) and viral RNA by RT-PCR (Figure, panel B) (Appendix).

Viral decay, measured using TCID50 for infectious virus and RNA copies of the N gene detected by RT-PCR, occurred over a 14-day period (Table). At day 1 we observed a 50% reduction of infectious virus and 48.8% loss of viral RNA (Figure, panels A, B). By day 5, levels of infectious virus had fallen by 96.5%, whereas viral RNA remained at 48.2% compared with day 0 (Figure, panels C, D). At day 14 only 0.7% of the initial infectious virus and 17% of viral RNA remained. Plenzig et al. (7) detected viral RNA in 2 exhumed corpses at 3 months postmortem, despite an absence of infectious virus. We used hematoxylin and eosin staining to detect viral nucleoprotein in lung tissue. We observed persistent antigen staining until day 5; by day 14, only 1 of 3 samples had detectable staining (Appendix Figure).

We euthanized the mice 5 days after infection, when the lungs had a high viral load. However, COVID-19 deaths usually occur during later stages of disease, by which time infectious viral load has decreased from the peak usually seen early during the symptomatic phase of the illness (10). We detected virus antigen in the lungs of all mice at 5 days postmortem; infectious virus had declined by 96.48%, but viral RNA declined by only 48.21%. Our results shows that infectious virus declines earlier than viral RNA or antigen in postmortem tissues.

These findings have implications for the safe handling of deceased COVID-19 patients. Infectious virus can persist on inanimate surfaces for up to 14 days at lower temperatures (<4°C), but rapidly decays in postmortem tissue samples. We observed a 96.5% decrease in infectious virus by day 5 and a 99.3% decrease by day 14. Most published postmortem studies in humans have reported viral load at the time of death using cycle threshold values rather than N gene copies as we have done; results range from 17–36 for cycle threshold values and 0–5.49 log10 for N gene copies (11). Therefore, the maximum potential risk of transmission from an infected corpse is during the first 24 hours after death. By day 5, the amount of infectious virus has decreased by 96.48%. If proper biosafety precautions and personal protective equipment are used to handle the corpse during autopsy or preparation for burial or cremation, we believe that the burial or cremation process is unlikely to spread disease.

Dr. Valkenburg is a viral immunologist at the HKU-Pasteur Research Pole, University of Hong Kong, Hong Kong, China. Her research interests include immune correlates for influenza and severe acute respiratory syndrome coronavirus 2.

Top

Acknowledgment

This study was partly supported by the Health and Medical Research Fund (grant no. HMRF COVID-190115 to M.P. and S.A.V.), and Commissioned Research on Control of Infectious Diseases (phase III and IV) from the Health and Medical Research Fund (M.P.).

Top

References

  1. Chin  AWH, Chu  JTS, Perera  MRA, Hui  KPY, Yen  HL, Chan  MCW, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe. 2020;1:e10. DOIPubMedGoogle Scholar
  2. Heinrich  F, Meißner  K, Langenwalder  F, Püschel  K, Nörz  D, Hoffmann  A, et al. Postmortem stability of SARS-CoV-2 in nasopharyngeal mucosa. Emerg Infect Dis. 2021;27:32931. DOIPubMedGoogle Scholar
  3. Skok  K, Stelzl  E, Trauner  M, Kessler  HH, Lax  SF. Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. Virchows Arch. 2021;478:34353. DOIPubMedGoogle Scholar
  4. Sablone  S, Solarino  B, Ferorelli  D, Benevento  M, Chironna  M, Loconsole  D, et al. Post-mortem persistence of SARS-CoV-2: a preliminary study. Forensic Sci Med Pathol. 2021;17:40310. DOIPubMedGoogle Scholar
  5. Schröder  AS, Edler  C, Ondruschka  B, Püschel  K, Schädler  J, Heinemann  A, et al. The handling of SARS-CoV-2 associated deaths - infectivity of the body. Forensic Sci Med Pathol. 2021;17:4118. DOIPubMedGoogle Scholar
  6. Plenzig  S, Bojkova  D, Held  H, Berger  A, Holz  F, Cinatl  J, et al. Infectivity of deceased COVID-19 patients. Int J Legal Med. 2021;135:205560. DOIPubMedGoogle Scholar
  7. Plenzig  S, Holz  F, Bojkova  D, Kettner  M, Cinatl  J, Verhoff  MA, et al. Detection and infectivity of SARS-CoV-2 in exhumated corpses. Int J Legal Med. 2021; Epub ahead of print. DOIPubMedGoogle Scholar
  8. Zheng  J, Wong  LR, Li  K, Verma  AK, Ortiz  ME, Wohlford-Lenane  C, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021;589:6037. DOIPubMedGoogle Scholar
  9. Perera  RAPM, Tso  E, Tsang  OTY, Tsang  DNC, Fung  K, Leung  YWY, et al. SARS-CoV-2 virus culture and subgenomic RNA for respiratory specimens from patients with mild coronavirus disease. Emerg Infect Dis. 2020;26:27014. DOIPubMedGoogle Scholar
  10. Zou  L, Ruan  F, Huang  M, Liang  L, Huang  H, Hong  Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:11779. DOIPubMedGoogle Scholar
  11. Nienhold  R, Ciani  Y, Koelzer  VH, Tzankov  A, Haslbauer  JD, Menter  T, et al. Two distinct immunopathological profiles in autopsy lungs of COVID-19. Nat Commun. 2020;11:5086. DOIPubMedGoogle Scholar

Top

Figures
Table

Top

Suggested citation for this article: Valkenburg SA, Cheng SMS, Hachim A, Peiris M, Nicholls J. Postmortem stability of SARS-CoV-2 in mouse lung tissue. Emerg Infect Dis. 2021 Dec [date cited]. https://doi.org/10.3201/eid2712.211621

DOI: 10.3201/eid2712.211621

Original Publication Date: September 23, 2021

Table of Contents – Volume 27, Number 12—December 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

John Nicholls, Block T, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong, China

Send To

10000 character(s) remaining.

Top

Page created: September 21, 2021
Page updated: September 23, 2021
Page reviewed: September 23, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external